Aducanumab: a new phase in therapeutic development for Alzheimer's disease?. Issue 8 (2nd August 2021)

• Record Type: Journal Article
• Authors: Lalli, Giovanna; Schott, Jonathan M; Hardy, John; De Strooper, Bart
• Is Part Of: EMBO molecular medicine. Volume 13:Issue 8(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-08-02
• Subjects: Molecular biology -- Periodicals; Medical genetics -- Periodicals; Pathology, Molecular -- Periodicals; 616.04205
• DOI: 10.15252/emmm.202114781
• Languages: English
• ISSNs: 1757-4676

Abstract

Abstract : On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (or Aβ) plaques from the brain. Abstract : G. Lalli, J. Schott, J. Hardy, and B De Strooper comment on the FDA approval of aducanumab and provide some interesting points to consider.